Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti – a case report

被引:0
作者
S. Kunzmann
T. Ngyuen
A. Stahl
J. M. Walz
M. M. Nentwich
C. P. Speer
K. Ruf
机构
[1] Bürgerhospital Frankfurt am Main,Department of Neonatology and Pediatric Intensive Care Medicine
[2] University of Würzburg,Children’s Hospital
[3] University Medicine Greifswald,Department of Ophthalmology
[4] University of Freiburg,Eye Center, Medical Center, Faculty of Medicine
[5] European Foundation for the Care of Newborn Infants (EFCNI),Eye Center, Medical Center, Faculty of Medicine
[6] University of Würzburg,undefined
来源
BMC Pediatrics | / 19卷
关键词
Necrotizing enterocolitis; Incontinentia pigmenti; Bevacizumab; Retinopathy; VEGF;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 142 条
[1]  
Phan TA(2005)Incontinentia pigmenti case series: clinical spectrum of incontinentia pigmenti in 53 female patients and their relatives Clin Exp Dermatol 30 474-480
[2]  
Wargon O(1993)Incontinentia pigmenti (Bloch-Sulzberger syndrome) J Med Genet 30 53-59
[3]  
Turner AM(2000)Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The international Incontinentia Pigmenti (IP) consortium Nature 405 466-472
[4]  
Landy SJ(2002)Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology J Am Acad Dermatol 47 169-187
[5]  
Donnai D(2011)Incontinentia pigmenti--ophthalmological observation of a series of cases and review of the literature Br J Ophthalmol 95 11-16
[6]  
Smahi A(2017)Successful treatment of refractory proliferative retinopathy of Incontinentia Pigmenti by intravitreal Ranibizumab as adjunct therapy in a 4-year-old child Retin Cases Brief Rep 11 352-355
[7]  
Courtois G(2018)Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity Cochrane Database Syst Rev 1 CD009734-615
[8]  
Vabres P(2011)Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 603-266
[9]  
Yamaoka S(2018)The role of tumor angiogenesis as a therapeutic target in colorectal cancer Expert Rev Anticancer Ther 18 251-1795
[10]  
Heuertz S(2007)Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 96 1788-376